Show simple item record

dc.contributor.authorDaly, Patricia E
dc.contributor.authorDunne, Mary T
dc.contributor.authorO'Shea, Carmel M
dc.contributor.authorFinn, Marie A
dc.contributor.authorArmstrong, John G
dc.date.accessioned2012-09-13T09:23:44Z
dc.date.available2012-09-13T09:23:44Z
dc.date.issued2012-07
dc.identifier.citationThe effect of short term neo-adjuvant androgen deprivation on erectile function in patients treated with external beam radiotherapy for localised prostate cancer: an analysis of the 4- versus 8-month randomised trial (Irish Clinical Oncology Research Group 97-01). 2012, 104 (1):96-102 Radiother Oncolen_GB
dc.identifier.issn1879-0887
dc.identifier.pmid22682750
dc.identifier.doi10.1016/j.radonc.2012.05.001
dc.identifier.urihttp://hdl.handle.net/10147/243768
dc.description.abstractErectile dysfunction is a common consequence of external beam radiotherapy (EBRT) for prostate cancer. The addition of neo-adjuvant androgen deprivation (NAD) has an indeterminate additive effect. We examined the long-term effect on erectile function (EF) of two durations (4 months: arm 1 and 8 months: arm 2) of NAD prior to radiation (RT) for patients with localised prostate cancer from the Irish Clinical Oncology Research Group (ICORG 97-01) 4- versus 8-month trial. In this study we aimed to (1) analyse the overall effect on EF of NAD in an EBRT population, (2) compare the probability of retained EF over time in an EBRT population treated with either 4 or 8 months of NAD and (3) identify any variables such as risk group and age which may have an additive detrimental effect. This analysis provides unique long term follow up data.
dc.language.isoenen
dc.publisherElsevieren_GB
dc.rightsArchived with thanks to Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncologyen_GB
dc.titleThe effect of short term neo-adjuvant androgen deprivation on erectile function in patients treated with external beam radiotherapy for localised prostate cancer: an analysis of the 4- versus 8-month randomised trial (Irish Clinical Oncology Research Group 97-01).en_GB
dc.typeOtheren
dc.contributor.departmentDepartment of Radiation Oncology, St. Luke's Hospital, Dublin, Ireland. trish_daly@eircom.neten_GB
dc.identifier.journalRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncologyen_GB
dc.description.provinceLeinsteren
html.description.abstractErectile dysfunction is a common consequence of external beam radiotherapy (EBRT) for prostate cancer. The addition of neo-adjuvant androgen deprivation (NAD) has an indeterminate additive effect. We examined the long-term effect on erectile function (EF) of two durations (4 months: arm 1 and 8 months: arm 2) of NAD prior to radiation (RT) for patients with localised prostate cancer from the Irish Clinical Oncology Research Group (ICORG 97-01) 4- versus 8-month trial. In this study we aimed to (1) analyse the overall effect on EF of NAD in an EBRT population, (2) compare the probability of retained EF over time in an EBRT population treated with either 4 or 8 months of NAD and (3) identify any variables such as risk group and age which may have an additive detrimental effect. This analysis provides unique long term follow up data.


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record